These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine. Ferri C; Croce G; Desideri G Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492 [TBL] [Abstract][Full Text] [Related]
45. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Khan NA; McAlister FA; Lewanczuk RZ; Touyz RM; Padwal R; Rabkin SW; Leiter LA; Lebel M; Herbert C; Schiffrin EL; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; DeChamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Campbell NR; Arnold M; Moe G; Hill MD; Jones C; Larochelle P; Ogilvie RI; Tobe S; Houlden R; Burgess E; Feldman RD; Can J Cardiol; 2005 Jun; 21(8):657-72. PubMed ID: 16003449 [TBL] [Abstract][Full Text] [Related]
46. What does nisoldipine coat core (CC) add to current therapy that is clinically meaningful? Opie LH Am J Cardiol; 1997 May; 79(10A):29-32; discussion 47-8. PubMed ID: 9186064 [TBL] [Abstract][Full Text] [Related]
51. Drug treatment of stable angina pectoris in the elderly: defining the place of calcium channel antagonists. Kumar S; Hall RJ Drugs Aging; 2003; 20(11):805-15. PubMed ID: 12964887 [TBL] [Abstract][Full Text] [Related]
52. Clinical pharmacokinetics of nisoldipine coat-core. Heinig R Clin Pharmacokinet; 1998 Sep; 35(3):191-208. PubMed ID: 9784933 [TBL] [Abstract][Full Text] [Related]
53. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients. Munakata M; Nagasaki A; Nunokawa T; Sakuma T; Kato H; Yoshinaga K; Toyota T Am J Hypertens; 2004 Nov; 17(11 Pt 1):1050-5. PubMed ID: 15533733 [TBL] [Abstract][Full Text] [Related]
54. Treatment of hypertension from volume to vasoconstriction: The ACE up your sleeve. Stanley JC; Samson RH Semin Vasc Surg; 2002 Dec; 15(4):225-36. PubMed ID: 12478497 [TBL] [Abstract][Full Text] [Related]
55. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075 [TBL] [Abstract][Full Text] [Related]
56. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker. Kuti EL; Baker WL; White CM Curr Med Res Opin; 2007 Jun; 23(6):1239-44. PubMed ID: 17559720 [TBL] [Abstract][Full Text] [Related]
57. T-channel-selective calcium channel blockade: a promising therapeutic possibility, only preliminarily tested so far: a review of published data. T-Channel Calcium Channel Blocker Study Group. Van der Vring JA; Cleophas TJ; Van der Wall EE; Niemeyer MG Am J Ther; 1999 Jul; 6(4):229-33. PubMed ID: 11329102 [TBL] [Abstract][Full Text] [Related]
58. Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Todd PA; Faulds D Drugs; 1992 Aug; 44(2):251-77. PubMed ID: 1382018 [TBL] [Abstract][Full Text] [Related]
60. Correlation between predicted theoretical mechanistic biochemistry (TMB) data and therapeutic effects in the management of vascular disorders with calcium channel blockers. Akintonwa DA; Odigwe CO Med Hypotheses; 2000 Jun; 54(6):944-7. PubMed ID: 10867744 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]